How to Reconstitute Egrifta (Tesamorelin): Storage and Stability After Mixing

What Is Egrifta (Tesamorelin) and Why Reconstitution Matters

Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH). The FDA approved the original Egrifta formulation in 2010 and the updated Egrifta SV (stabilized version) in 2019 for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. [1] It works by stimulating the pituitary gland to release endogenous growth hormone in a pulsatile, physiologic pattern rather than delivering exogenous GH directly.

Why Correct Reconstitution Changes Clinical Outcomes

Lyophilized peptides are freeze-dried powders held in a fragile molecular structure. Reconstitution technique determines how much active peptide survives into the final solution. Aggressive vortexing, the wrong diluent, or improper temperature can denature the protein before the needle ever touches skin.

Tesamorelin is a 44-amino-acid peptide conjugated to a trans-3-hexenoic acid group that improves metabolic stability. Even so, the conjugated peptide remains susceptible to hydrolysis and aggregation once dissolved. The manufacturer's post-approval stability studies, summarized in the current Egrifta SV prescribing information, show that reconstituted product degrades rapidly at room temperature. [2]

Who Uses Tesamorelin Outside the Labeled Indication

Compounding pharmacies dispense tesamorelin for off-label use in non-HIV adults seeking visceral fat reduction or age-related GH optimization. In those settings, bacteriostatic water (BAC water, 0.9% benzyl alcohol) replaces the supplied sterile water for injection, which extends usable shelf life. The FDA's compounding framework under 503A and 503B permits this, but stability data are not published by Help or any manufacturer. [3] Clinicians managing these patients must apply USP <797> Category 2 principles to estimate beyond-use dates.

FDA-Approved Egrifta SV Reconstitution: Step-by-Step Protocol

The prescribing information for Egrifta SV provides an exact reconstitution sequence that must not be improvised. [2] Every deviation, including using a different diluent volume or shaking the vial, risks product degradation and injection-site reactions.

Supplies You Need Before Starting

• One Egrifta SV 2 mg lyophilized vial
• One diluent vial (sterile water for injection, 2.1 mL, supplied in the kit)
• One or two 27 to 29 gauge, 0.5-inch (12.7 mm) insulin syringes (1 mL capacity)
• Alcohol swabs (70% isopropyl alcohol)
• A clean, flat surface and adequate lighting

Do not substitute bacteriostatic water in the FDA-approved kit. The supplied sterile water for injection is preservative-free and matched to the approved stability window, which is immediate use only.

The Reconstitution Steps

1. Remove both vials from the refrigerator. Let them sit at room temperature for approximately 5 minutes. Cold vials increase viscosity and can leave undissolved particles.
2. Wipe the rubber stopper of the diluent vial with an alcohol swab. Let it dry completely.
3. Draw exactly 2.1 mL of sterile water for injection into a syringe.
4. Inject the 2.1 mL into the Egrifta SV powder vial by aiming the stream at the glass wall, not directly onto the powder. This reduces foaming.
5. Roll the vial gently between your palms for 30 seconds. Do not shake or vortex. Shaking introduces air bubbles and can cause peptide aggregation.
6. Inspect the solution. It should be clear and colorless. Discard the vial if you see particulates, cloudiness, or a yellow tint.
7. Draw the full reconstituted volume back into the syringe. Tap the syringe barrel to move air bubbles to the top, then expel them before injection.

Injecting the Dose

Inject subcutaneously into the abdomen only. The prescribing information specifically prohibits injection into scar tissue, the navel area, or bruised skin. [2] Rotate the exact injection site daily within the abdominal region to reduce lipohypertrophy. After injecting, press the site lightly with a dry cotton ball; rubbing disperses the peptide unevenly.

Storage and Stability: Before and After Mixing

Unmixed (Lyophilized) Storage

Unopened Egrifta SV vials are refrigerated at 2 to 8°C (36 to 46°F). The labeled shelf life is 24 months from manufacture when stored correctly. [2] Freezing destroys lyophilized peptide cakes irreversibly. Transport vials in an insulated cooler with ice packs, never in direct contact with dry ice.

If a vial has been left at room temperature, the manufacturer permits storage at up to 25°C (77°F) for a maximum of 3 months, after which it must be discarded even if unused. This single-excursion window does not reset if the vial is returned to the refrigerator. [2]

Post-Reconstitution Stability (Brand Product)

The Egrifta SV prescribing information is direct: use the reconstituted solution immediately. Do not refrigerate it for later use. Do not pool leftover solution from one vial into another. Each vial covers exactly one daily dose. [2]

This zero-storage policy exists because sterile water for injection contains no antimicrobial preservative. A dissolved peptide in preservative-free aqueous solution is a growth medium for bacteria. Beyond the contamination risk, hydrolytic degradation of tesamorelin begins within hours in aqueous solution at neutral pH. [4]

Post-Reconstitution Stability (Compounded Tesamorelin with BAC Water)

Compounded tesamorelin vials from 503A pharmacies arrive as lyophilized or sometimes liquid-filled vials. When a lyophilized compounded vial is reconstituted with bacteriostatic water containing 0.9% benzyl alcohol, the benzyl alcohol inhibits microbial growth, extending the usable period.

USP <797> (2023 revision) assigns Category 2 beyond-use dates to compounded sterile preparations made with antimicrobial preservatives. Refrigerated Category 2 preparations with sterility data from the compounding pharmacy may carry a beyond-use date (BUD) of up to 45 days. Without that specific sterility testing documentation, the default BUD is 14 days refrigerated. [5]

The 14-day-refrigerated rule is the conservative clinical standard most prescribers apply. Write it on the vial label with the reconstitution date and time the moment you mix it.

HealthRX Stability Decision Framework for Compounded Tesamorelin:

| Diluent | Storage Temp | Maximum BUD | Basis | |---|---|---|---| | Sterile water for injection (brand kit) | Room temp | Use immediately | Egrifta SV PI [2] | | Bacteriostatic water, no sterility data from pharmacy | 2 to 8°C | 14 days | USP <797> Category 2 default [5] | | Bacteriostatic water, pharmacy provides sterility/potency data | 2 to 8°C | Up to 45 days | USP <797> Category 2 extended [5] | | Any diluent | Frozen | Not recommended | Potential aggregation on thaw |

Never use a vial that has exceeded its BUD, appears cloudy, contains visible particles, or smells unusual. When in doubt, discard.

Choosing the Right Syringe and Needle

Insulin Syringes: The Practical Standard

The 2 mg daily dose of tesamorelin occupies the full 2.1 mL reconstituted volume. A 1 mL insulin syringe cannot hold this volume in one draw. You will need either a 3 mL syringe with a 27 to 29 gauge, 0.5-inch needle, or two separate 1 mL insulin syringes drawn sequentially.

For patients self-injecting at home, the 3 mL syringe with a 29-gauge needle balances minimal dead space against comfort. Dead space (the volume trapped in the hub and needle after the plunger bottoms out) averages 0.07 to 0.15 mL in standard syringes. [6] With a 2 mg dose in 2.1 mL, losing even 0.1 mL to dead space means losing roughly 95 mcg of tesamorelin, or about 4.8% of the dose. Low dead-space (LDS) syringes reduce this to <0.01 mL.

Needle Length and Gauge Selection

| Patient Body Habitus | Recommended Gauge | Needle Length | |---|---|---| | Lean (BMI <25) | 29 to 30 gauge | 0.5 inch (12.7 mm) | | Average (BMI 25 to 30) | 28 to 29 gauge | 0.5 inch | | Higher BMI (>30) | 27 to 28 gauge | 0.5 to 0.625 inch |

Subcutaneous depth in the abdominal region averages 17 to 22 mm in adults with BMI between 25 and 35, so a 0.5-inch needle reliably reaches the subcutaneous space without penetrating muscle. [6] Intramuscular injection of tesamorelin is off-protocol and may alter absorption kinetics.

Dosing: Standard, Titration, and Monitoring

Standard Tesamorelin Dose

The FDA-approved dose is 2 mg once daily by subcutaneous injection. [1] The ENCORE trial (N=545) confirmed this dose reduced visceral adipose tissue by a mean of 18.1% vs. 0.5% with placebo at 26 weeks (P<0.0001). [7] No dose-escalation regimen is approved for the labeled indication.

Off-Label Dosing in Non-HIV Adults

Compounding prescriptions for non-HIV patients typically range from 1 mg to 2 mg daily, sometimes split into 0.5 to 1 mg twice daily to mimic more physiologic GH pulsatility. No randomized controlled trial has established a superior dose or frequency outside the HIV indication. Endocrine Society Clinical Practice Guidelines (2019) do not endorse tesamorelin for age-related GH decline. [8]

Monitoring Parameters

The Endocrine Society states: "Measurement of IGF-1 levels is recommended to assess the GH response and to detect excess GH secretion that could expose patients to long-term adverse effects." [8] Baseline IGF-1 should be drawn before starting tesamorelin. Recheck at 6 to 8 weeks after starting therapy, then every 6 months once stable.

Additional monitoring includes fasting glucose and HbA1c at baseline and every 6 months. Tesamorelin increases IGF-1, which can cause insulin resistance. In the F-004 trial (N=391), tesamorelin users showed a mean 0.12% increase in HbA1c vs. 0.02% in the placebo group at 52 weeks. [9]

Common Reconstitution Errors and How to Prevent Them

Error 1: Using Bacteriostatic Water with the Brand Kit

Adding BAC water to the Egrifta SV vial supplied in the commercial kit invalidates the FDA-approved stability data and subjects the patient to benzyl alcohol that was not formulated for this product's specific pH and buffer system. Use only the diluent supplied.

Error 2: Shaking the Vial

Peptides foam when shaken. Foaming causes air-water interfaces where protein denaturation occurs fastest. Rolling the vial gently between the palms is sufficient and keeps the powder-to-liquid contact gentle. A 2017 review in the Journal of Pharmaceutical Sciences confirmed that air-water interface shear stress is the dominant degradation pathway for therapeutic peptides in aqueous solution. [4]

Error 3: Drawing Air Into the Syringe Before Injecting Into the Vial

Some patients try to inject air into the vial to create positive pressure for easier drawing. With single-use, preservative-free vials, introducing air adds an oxidative stress and raises contamination risk. Use negative pressure by simply pulling the plunger back after inserting the needle; the pressure differential in a sealed vial is sufficient.

Error 4: Storing Reconstituted Brand Product

Even one hour of refrigerated storage of reconstituted Egrifta SV after the patient delays their injection is inconsistent with the labeling. The prescribing information does not authorize short-term refrigeration as an exception. [2] If a dose is missed, discard the reconstituted vial and open a new one for the next scheduled dose.

Error 5: Ignoring Injection-Site Rotation

Fixed injection sites lead to lipohypertrophy, a fibrous fatty change in subcutaneous tissue that alters peptide absorption. A systematic review in Diabetes Care found that injecting insulin into lipohypertrophic tissue increased dose variability by up to 25%. [10] The same mechanism applies to any subcutaneously administered peptide.

Special Populations and Contraindications

Contraindications

The Egrifta SV prescribing information lists the following absolute contraindications: active malignancy or a history of malignancy that has not been treated with curative intent, hypersensitivity to tesamorelin or mannitol, pregnancy, prior pituitary surgery or radiation to the head or neck area that disrupts GHRH signaling, and known disruption of the hypothalamic-pituitary axis from tumors, trauma, or surgery. [2]

Benzyl alcohol in BAC water is contraindicated in neonates and has been associated with gasping syndrome in premature infants. Adult patients with a history of benzyl alcohol hypersensitivity should use the brand kit's supplied sterile water diluent, even in compounding contexts.

Renal and Hepatic Impairment

Tesamorelin is a peptide and undergoes ubiquitous proteolytic degradation. No dose adjustment is required for renal or hepatic impairment based on the current prescribing information. [2] The clinical pharmacology section of the Egrifta SV label shows no significant difference in AUC across mild-to-severe renal impairment categories.

Drug Interactions

Tesamorelin stimulates GH release, which in turn stimulates IGF-1 and can modulate CYP450 enzyme activity. The prescribing information notes a potential interaction with drugs metabolized by CYP3A4, including cyclosporine and antiretrovirals. [2] Corticosteroids blunt GHRH-mediated GH release; patients on chronic systemic corticosteroids may show a reduced tesamorelin response. Patients taking insulin or oral hypoglycemics require closer glucose monitoring given tesamorelin's effects on insulin sensitivity.

Practical At-Home Administration Checklist

Patients managing self-injection benefit from a standardized daily routine. The Endocrine Society emphasizes that injection technique education reduces both adverse events and wasted product in subcutaneous peptide therapy programs. [8]

Before injection:

• Wash hands for 20 seconds with soap and water.
• Remove vial from the refrigerator 5 minutes before reconstitution.
• Check expiration and BUD on the label.
• Inspect the vial for cracks or particulates.

During injection:

• Pinch an inch of abdominal skin between two fingers.
• Insert the needle at a 45 to 90 degree angle depending on subcutaneous depth.
• Inject slowly over 5 to 10 seconds.
• Release the skin before withdrawing the needle.

After injection:

• Discard the syringe in an FDA-cleared sharps container immediately.
• Log the injection site, time, and lot number of the vial.
• Refrigerate any remaining compounded vials promptly; do not leave them at room temperature.

The FDA's guidance on safe injection practices recommends that patients never reuse syringes or needles and always use a proper sharps disposal container. [11]